Portfolio: Life Science
LU Ventures’ portfolio companies, pipeline, and exits — emerged from Lund University. Our life science portfolio spans medtech, e-health, pharma, ATMP, synthetic biology, foodtech and diagnostics. This page is updated regularly.
Medtech & E-health
Pharmaceuticals, ATMPs & synthetic biology
Diagnostics
Labtech
Foodtech
Pipeline: What’s next?
Here are the projects and early-stage companies taking part in Business Track – LU Innovation and LU Ventures’ programme from research to first investment. Would you like to find out more, invest or get involved? Please email the contact person listed below.
The next generation of complex organoids
Phase: Project
Contact: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie)
A new injectable, electrically conductive and bioresorbable polymer
Phase: Incorporated – Adonel Therapeutics AB
Contact: per [dot] antonsson [at] innovation [dot] lu [dot] se (Per)
Gene therapy for epileptic seizures
Phase: Incorporated – PlexiGene AB
Contact: per [dot] antonsson [at] innovation [dot] lu [dot] se (Per)
Predicting epilepsy
Phase: Incorporated - Menteva AB
Contact: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie)
Antibody therapy for cancer
Phase:Incorporated - TheraComp AB
Contact: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie)
Treating thirst — without fluids
Stage: Incorporated – SitiSolv AB
Contact: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie)
Choose the right drug candidate
Stage: Incorporated – Labbot Analytics AB
Contact: eddie [dot] thordarson [at] innovation [dot] lu [dot] se (Eddie)
Alumni and exits
Since its inception in the 1990s, LU Ventures has helped launch over 150 spin-off companies from Lund University. We are proud of the impact made by our portfolio companies and alumni, as well as our track record of successful IPOs and acquisitions by global industry players. Read more about LU Ventures and how we work here.
Below is a selection of our exits.
Saga Diagnostics Acquired by Roche (Foundation Medicine) for up to 595 Million USD
LU Ventures’ portfolio company SAGA Diagnostics has been acquired by Roche (Foundation Medicine). Read more about the transaction in the press release from Foundation Medicine.
Would you like to find out more or co-invest with us?
Contact our Life Sciences team
Find direct contact details for our venture builders in medicine and life sciences.
We are LU Ventures
Find out more about how LU Ventures operates, our mandate, phases and investment criteria.
Explore the tech portfolio
Our portfolio comprises both life sciences and deep tech companies. Explore the technology companies.
Are you a researcher at Lund University? Find out more about the Business Track here → Programme: Business Track.